Presentation Abstract

Session: APS.720.04-Hypertension: Clinical---Gender, Kidney, Sleep, the Elderly and Blood Pressure
Presentation: 17557 - Does Renal Denervation Stopp Renal Function Decline in Treatment Resistant Hypertension: Results of a Pilot Study
Pres Time: Wednesday, Nov 20, 2013, 9:30 AM -11:00 AM
Location: Hall F, Core 7, Poster Board: 7077
Pres. Time: Wednesday, Nov 20, 2013, 9:30 AM -11:00 AM
Specialty: +720. Hypertension: Clinical
Keywords: Ablation, radiofrequency; Renal function; Hypertension
Authors: Roland E Schmieder, Univ Hosp Erlangen, Erlangen, Germany; Felix Mahfoud, Univ Hosp Saarland, Homburg, Germany; Axel Schmid, Tilmann Ditting, Roland Veelken, Michael Uder, Univ Hosp Erlangen, Erlangen, Germany; Michael Böhm, Univ Hosp Saarland, Homburg/Saar, Germany; Christian Ott, Univ Hosp Erlangen, Erlangen, Germany
Abstract: Background: Renal denervation (RDN) emerged as an innovative interventional antihypertensive therapy in patients with treatment resistant hypertension. Since arterial hypertension is a predominant risk factor of renal function decline over time and achieving blood pressure (BP) targets preserves renal function, we analysed whether reducing BP by RDN preserves renal function.
Methods: 15 patients with treatment resistant hypertension (office BP ≥140/90 mmHg, while on at least 3 antihypertensives, confirmed by 24-h ABPM ≥130/80 mmHg) and chronic kidney disease (CKD) stage 3 and 4 (estimated glomerular filtration rate (eGFR) 15-60 ml/min/1.73m²) underwent catheter-based RDN using the Symplicity FlexTM catheter (Medtronic Inc., Palo Alto, CA). The study was registered at www.clinicaltrials.gov (ID: NCT01442883). Renal function was evaluated up to 3 years prior and till 1 year after RDN. The change in eGFR over time was calculated by regression slope individually for each patient. Central hemodynamics were assessed using pulse wave analysis (SphygmoCorTM System, AtCor Medical, Sydney, Australia).
Results: Patients (66 ± 8 years) were treated with 5.8 ± 1.2 antihypertensive drugs on average, and about 3/4 had type-2 diabetes. One year after RDN, brachial office BP was reduced by 26/6 mmHg (systolic: 167 ± 22 versus 141 ± 11 mmHg, p=0.004; diastolic: 78 ± 13 versus 73 ± 9 mmHg, p=0.079), aortic systolic BP by 24 mmHg (150 ± 17 versus 126 ± 11 mmHg, p=0.001), and average systolic 24-h ABPM by 13 mmHg (157 ± 13 versus 144 ± 12 mmHg, p=0.028). Before RDN mean eGFR decline was -5.6 ml/min/1.73m2 per year, and eGFR remained stable or even increased after RDN (baseline: 47.0 ± 11 versus 1 year: 49.2 ± 14 ml/min/1.73m2), with a significant difference between eGFR change before and after RDN (-5.6±4.4 versus +2.2±8.0 ml/min/1.73m2 per year, p=0.021). None of the patients developed a doubling of serum creatinine or required dialysis after RDN at any point of time.
Conclusion: Our pilot study data indicate that interventional treatment of hypertension with RDN decreases BP and, most importantly, slows or even halts the decline of renal function in treatment resistant hypertensive patients with CKD.
Disclosures:   R.E. Schmieder, Medtronic, Significant,Research Grant; Medtronic, Modest,Honoraria; Medtronic, Modest,Consultant/Advisory Board; F. Mahfoud, Medtronic, Significant,Research Grant; Medtronic, Modest,Honoraria; Medtronic, Modest,Consultant/Advisory Board; A. Schmid, None; T. Ditting, None; R. Veelken, None; M. Uder, None; M. Böhm, Astra Zeneca, Bayer AG, Boehringer Ingelheim, Novartis, Pfizer, Sanofi Aventis, Server, Adrian-Medtronic, Modest,Research Grant; Astra Zeneca, AWD Dresden, Bayer, Boehringer Ingelheim, Berlin-Chemie, Daiichi-Sankyo, MSD, Novartis, Pfizer, Sanofi-Aventis, Servier, Medtronic, Modest,Speakers Bureau; Astra Zeneca, Bayer AG, Boehringer Ingelheim, Daiichi-Sankyo, MSD, Novartis, Pfizer, Sanofi-Aventis, Servier, Modest,Consultant/Advisory Board; C. Ott, None.



Mobile App Technical Support
support@doubledutch.me
(questions related to the DoubleDutch mobile app and not this planner)


Online Planner and Itinerary Builder Technical Support
(questions related to this planner and not the mobile app)
217-398-1792
Helpdesk